Physician profile
Daniel Arnold Aldea
NPI 1104385319
$3,653.02
in general payments reported to CMS, 2019-2025
22 companies · $1,595 in 2025
The $1,595 reported for 2025 was more than what 96% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $794 · 2024: $1,265 · 2025: $1,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,554 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,553.76 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aop Health US, LLC | $475.09 | 2025 | Rapiblyk |
| Abiomed | $451.27 | 2023-2025 | Impella |
| Shockwave Medical, INC | $348.73 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Novartis Pharmaceuticals Corporation | $341.05 | 2023-2025 | |
| Pfizer INC. | $336.03 | 2023-2025 | |
| Abbott Laboratories | $321.49 | 2023-2025 | Ensite, Coroflow, Pressurewire |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $263.02 | 2023-2025 | Lifevest |
| Edwards Lifesciences Corporation | $146.92 | 2025 | Sapien 3 Ultra Resilia |
| Janssen Pharmaceuticals, INC | $141.81 | 2024 | Xarelto |
| Boston Scientific Corporation | $125.00 | 2023 | Ekosonic |
| Novo Nordisk INC | $102.77 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $100.65 | 2023-2024 | Camzyos |
| Terumo Medical Corporation | $92.95 | 2023 | Tr Band, Glidewire |
| Scpharmaceuticals INC. | $86.81 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $61.96 | 2023-2024 | Inpefa |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $57.39 | 2024 | Winrevair |
| United Therapeutics Corporation | $42.21 | 2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $41.50 | 2023-2025 | Wainua, Farxiga |
| Regeneron Healthcare Solutions, INC. | $35.55 | 2025 | Evkeeza |
| Baxter Healthcare | $35.44 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $24.28 | 2023 | Definity |
| Heartflow, INC. | $21.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Aldea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.